Aprobación de fda de stock itci
View the latest ITCI stock quote and chart on MSN Money. Dive deeper with interactive charts and top stories of INTRA-CELLULAR THERAPIES, INC.. Intra-cellular therapies insider Christopher Alafi PhD bought $4.7 million of ITCI stock when investors sold the stock after FDA news. 11/4/2019 · Intra-Cellular Therapies (ITCI) Stock Plunges on Schizophrenia Drug Failure, Downgrade IntraCellular Therapies (ITCI) said patients in a schizophrenia drug trial responded better to the placebo medication. 12/24/2019 · Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. * Drugs@FDA includes information about drugs, including biological products, approved for human use in the United States (see FAQ), but does not include information about FDA-approved products regulated by the Center for Biologics Evaluation and Research (for example, vaccines, allergenic products, blood and blood products, plasma derivatives
Intra-Cellular Therapies, Inc. (ITCI) News - Find the latest company news headlines for Intra-Cellular Therapies, Inc.
Membership is Free What are you waiting for? Sign up now! Name: Username available! ITCI | Complete Intra-Cellular Therapies Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 12/9/2019 · Looking for insights on Intra-cellular-therapies (NASDAQ:ITCI) stock? View ITCI's stock ratings, price targets, earnings, commentary and news at Smarter Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders.
View detailed financial information, real-time news, videos, quotes and analysis on Intra-Cellular Therapies Inc. (NASDAQ:ITCI). Explore commentary on Intra-Cellular Therapies Inc. and hear what the experts at TheStreet are saying about ITCI.
12/27/2019 · Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 12/30/2019 · Real time Intra-Cellular Therapies (ITCI) stock price quote, stock graph, news & analysis. FDA announcements can make or break a stock. Intra-Cellular Therapies, Inc. has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize its proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here . Intra-Cellular Therapies (NASDAQ: ITCI ) 30 day option implied volatility is at 120; compared to its 52-week range of 60 to 363 as shares rally 160 after announces FDA approval of CAPLYTA.
12/27/2019 · Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time.
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for July 31, 2019 to discuss the New 12/31/2019 · ITCI.O. Latest Trade. 35.23 USD. FDA Approves Intra-Cellular Therapies * Intra-Cellular Therapies announces proposed public offering of common stock. ITCI had returned +1.52% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period. More Info About Intra-Cellular Therapies Inc. (ITCI) Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. Adagio Medical fait part de l'approbation d'une exemption des dispositifs de recherche du FDA des États-Unis avec conditions afin d'effectuer une étude clinique pour le traitement de la fibrillation auriculaire permanente faisant appel au système de cryoablation par température ultra basse 12/27/2019 · Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. View detailed financial information, real-time news, videos, quotes and analysis on Intra-Cellular Therapies Inc. (NASDAQ:ITCI). Explore commentary on Intra-Cellular Therapies Inc. and hear what the experts at TheStreet are saying about ITCI.
12/24/2019 · Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults.
11/4/2019 · Intra-Cellular Therapies (ITCI) Stock Plunges on Schizophrenia Drug Failure, Downgrade IntraCellular Therapies (ITCI) said patients in a schizophrenia drug trial responded better to the placebo medication. 12/24/2019 · Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. * Drugs@FDA includes information about drugs, including biological products, approved for human use in the United States (see FAQ), but does not include information about FDA-approved products regulated by the Center for Biologics Evaluation and Research (for example, vaccines, allergenic products, blood and blood products, plasma derivatives
12/24/2019 · ITCI was one of the big stocks on our radar today. Intra-Cellular Therapies ITCI was trading millions of shares in the premarket and was up WELL over 100%. 11/20/2017 · FDA has granted Fast Track designation to Intra-Cellular Therapies (NASDAQ:ITCI) for lumateperone for the treatment of schizophrenia. The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drug candidates to treat serious and life-threatening conditions. 12/23/2019 · Intra-Cellular Therapies Inc. shares ITCI, -0.08% soared 38% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has approved a treatment for schizophrenia in adults. 8/23/2017 · ITCI Gains On FDA News. As mentioned above, Intra-Cellular Therapies is having a strong day in the market today after announcing some key FDA news. The company said that the United States Food and Drug Administration has informed them that it has completed the review of the company’s responses to requests from the FDA for additional information.